Devonian Health Reports Sharply Increased Losses, Low Cash; 60-to-1 Reverse Split Effected
DVHGF has more than doubled off its 52-week low of $0.6 on elevated volume (2.1× avg).
Summary
Devonian Health Group reported a significant increase in net loss for the three and six months ended January 31, 2026, with a quarterly net loss of $2.2 million ($0.81 per share) and a six-month net loss of $3.8 million ($1.37 per share). The company's cash balance stood at a critically low $1.3 million. Additionally, the company disclosed a 60-to-1 reverse stock split that was effected on January 22, 2026. The increased losses are primarily due to lower distribution revenues following the expiry of a key agreement, prompting a strategic pivot to focus on its biopharmaceutical pipeline, particularly Thykamine(TM).
This financial deterioration, coupled with the substantial reverse stock split, signals significant financial strain and potential challenges for the company. While positive preclinical data for Thykamine(TM) in MASH was reported, the company's ability to fund pivotal clinical studies for its pipeline is questionable given its current cash position. Traders will be closely monitoring the company's efforts to secure financing and evaluate strategic alternatives for its non-core business to support its biopharmaceutical development.
At the time of this announcement, DVHGF was trading at $10.65 on OTC in the Life Sciences sector, with a market capitalization of approximately $29.5M. The 52-week trading range was $0.60 to $39.59. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.